Jan. 27 Quick Takes: European label expansions for Rinvoq, Keytruda; plus GBT, BeiGene and Pfizer

European label expansion for AbbVie’s Rinvoq
The European Commission approved Rinvoq upadacitinib from AbbVie Inc. (NYSE:ABBV) to treat psoriatic arthritis and ankylosing spondylitis. The oral JAK-1 inhibitor is approved in the U.S. and EU to treat rheumatoid arthritis. 

EC approves Keytruda for MSI-H or dMMR colorectal cancer
The EC approved Keytruda pembrolizumab from Merck & Co. (NYSE:MRK) as monotherapy for first-line treatment of patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer, marking the PD-1 inhibitor’s first gastrointestinal indication in Europe. ...